Screener
Tarsus Pharmaceuticals, Inc. TARS Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s other non-current liabilities?
- Tarsus Pharmaceuticals, Inc. (TARS) reported other non-current liabilities of $15.9M in Q2 2026.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s other non-current liabilities?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s other non-current liabilities has grown at a 77.3% compound annual growth rate (CAGR), from $605K to $10.6M.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude